Pharmacy Times
DECEMBER 23, 2024
The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.
Drug Topics
DECEMBER 26, 2024
Check out this list of our top 5 most read cardiology stories from the year 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 20, 2024
With pressure from the House GOP, expected PBM reform was not included in Congress end-of-year spending package.
The Checkup by Singlecare
DECEMBER 20, 2024
Mixing alcohol with metoprolol can come with various side effects, some of which can be serious. Many people take metoprolol, either as metoprolol tartrate or metoprolol succinate , to help manage high blood pressure and heart conditions. If youre considering drinking alcohol while taking this prescription drug, you should know the possible risks. For some people who know how they react to the medication and alcohol, drinking in moderation may be doable.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
DECEMBER 19, 2024
Most of the formularies run by some of the largest health plans in the U.S. generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Almost uniformly, the 11 formularies made the drugs available fairly when judged on three criteria: eligibility based on clinical data, restrictions placed on prescribers, and step therapy, which requires patients to try other
Fierce Pharma
DECEMBER 23, 2024
The company already moved to cut its entire commercial sales force following several FDA setbacks in its efforts to introduce sotagliflozin in diabetes.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
DECEMBER 24, 2024
Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.
The Checkup by Singlecare
DECEMBER 19, 2024
Tens of millions of people start their day with coffee without a second thoughtmany even find it difficult to have any thoughts at all before their first cup. But if youre taking prescription drugs on a regular basis, such as Linzess (the brand name for linaclotide), you may be wondering if you need to rethink your morning joe. Linzess is an oral medication that is approved by the Food and Drug Administration for the treatment of irritable bowel syndrome with constipation (IBS-C) as well as chro
STAT
DECEMBER 20, 2024
Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market. The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday.
pharmaphorum
DECEMBER 19, 2024
At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
DECEMBER 19, 2024
The lawsuit alleges that the company knowingly violated both the Controlled Substances Act and the False Claims Act.
Pharmacy Times
DECEMBER 24, 2024
Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.
The Checkup by Singlecare
DECEMBER 19, 2024
Originally approved to help people with Type 2 diabetes, the class of medications known as GLP-1 agonists and dual GIP/GLP-1s quickly acquired a reputation for helping people shed stubborn pounds. As a result, the use of medications like Ozempic , Wegovy , Zepbound , Rybelsus , and Mounjaro has skyrocketed, as people turned to these medications to help them lose weightcausing drug shortages and creating a market for compounded versions of these brand-name drugs.
STAT
DECEMBER 19, 2024
The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection. The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
DECEMBER 24, 2024
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
Drug Topics
DECEMBER 24, 2024
Check out this list of our top 5 most read COVID-19 stories from the year 2024.
Pharmacy Times
DECEMBER 21, 2024
The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).
Fierce Pharma
DECEMBER 19, 2024
Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. | Following in the footsteps of Pfizer, Roche and Takeda, another ALK inhibitor has made its belated entry into the U.S. The FDA nod comes four years after its initial approval in China.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Med Ed 101
DECEMBER 22, 2024
I’ve put together an approximately 20-minute video on the BCMTMS exam and what you can expect for 2025. General information on the 2025 BCMTMS Exam Who writes the exam? – National Board of Medication Therapy Management Eligibility ASK EMPLOYER IF THEY WILL HELP PURCHASE STUDY MATERIALS AND TEST COSTS!!!! About The BCMTMS Exam Content Domains […] The post 2025 BCMTMS Exam – How To Prepare?
pharmaphorum
DECEMBER 24, 2024
AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU for a form of early-stage lung cancer.
Drug Topics
DECEMBER 23, 2024
Check out this list of our top 5 most read Drug Topics stories from the year 2024.
Pharmacy Times
DECEMBER 24, 2024
The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.
Fierce Healthcare
DECEMBER 20, 2024
HHS released a list of 64 drugs on Friday that will have reduced co-insurance for patients with Medicare Part B. The discounts come from the Inflation Reduction Act which requires drug makers to give rebates to the federal government when a drug's cost rises more than inflation.
STAT
DECEMBER 19, 2024
CVS Health was accused of contributing to a nationwide epidemic of opioid addiction and overdose by filling illegal opioid prescriptions and billing federal health insurance programs, according to a lawsuit unsealed Wednesday by the U.S. Department of Justice. The lawsuit alleged that, since October 2013, CVS knowingly filled prescriptions for “dangerous and excessive quantities” of controlled substances that lacked a legitimate medical purpose, were not valid, and were not issued
Drug Topics
DECEMBER 23, 2024
Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.
Pharmacy Times
DECEMBER 20, 2024
Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.
Fierce Pharma
DECEMBER 20, 2024
Perhaps PD-1 inhibitors just arent for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
STAT
DECEMBER 19, 2024
As we approach the end of 2024, First Opinion is publishing a series of essays on the state of AI in medicine and biopharma. “ How far away was Oswald from Kennedy? ” “ Major depressive disorder.
pharmaphorum
DECEMBER 24, 2024
The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
Pharmacy Times
DECEMBER 22, 2024
Clinical trials will seek to evaluate the immunogenicity and safety of the LBT-SA7 vaccine.
Fierce Pharma
DECEMBER 19, 2024
The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.
Fierce Healthcare
DECEMBER 23, 2024
Despite significant headwinds coming to bear over the past several years, healthcare executives are expecting a favorable 2025, according to a new survey from Deloitte.
Expert insights. Personalized for you.
123 
Let's personalize your content